Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.97M
2: EX-10.37 Material Contract HTML 33K
3: EX-23.1 Consent of Expert or Counsel HTML 27K
7: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 49K
Awarded Compensation
4: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
13: R1 Cover HTML 95K
14: R2 Audit Information HTML 32K
15: R3 Consolidated Balance Sheets HTML 124K
16: R4 Consolidated Balance Sheets (Parenthetical) HTML 37K
17: R5 Consolidated Statements of Operations and HTML 104K
Comprehensive Loss
18: R6 Consolidated Statements of Convertible Preferred HTML 117K
Stock, Redeemable Common Stock and Stockholders'
Equity (Deficit)
19: R7 Consolidated Statements of Cash Flows HTML 120K
20: R8 Nature of the Business and Basis of Presentation HTML 37K
21: R9 Summary of Significant Accounting Policies HTML 88K
22: R10 License, Collaboration, and Funding Agreements HTML 47K
23: R11 Fair Value of Financial Assets and Liabilities HTML 129K
24: R12 Property and Equipment, Net HTML 40K
25: R13 Accrued Expenses HTML 37K
26: R14 Long-Term Debt HTML 57K
27: R15 Leases HTML 56K
28: R16 Commitment and Contingencies HTML 33K
29: R17 Preferred and Common Stock Warrants HTML 81K
30: R18 Common Stock, Redeemable Common Stock and HTML 48K
Convertible Preferred Stock (converted to Common
Stock)
31: R19 Stock-Based Compensation HTML 87K
32: R20 Income Taxes HTML 89K
33: R21 Net Loss per Share HTML 52K
34: R22 Loss on Transfer of Nonfinancial Assets HTML 31K
35: R23 Summary of Significant Accounting Policies HTML 117K
(Policies)
36: R24 Summary of Significant Accounting Policies HTML 55K
(Tables)
37: R25 Fair Value of Financial Assets and Liabilities HTML 137K
(Tables)
38: R26 Property and Equipment, Net (Tables) HTML 39K
39: R27 Accrued Expenses (Tables) HTML 37K
40: R28 Long-Term Debt (Tables) HTML 52K
41: R29 Leases (Tables) HTML 55K
42: R30 Preferred and Common Stock Warrants (Tables) HTML 78K
43: R31 Stock-Based Compensation (Tables) HTML 75K
44: R32 Income Taxes (Tables) HTML 88K
45: R33 Net Loss per Share (Tables) HTML 52K
46: R34 Nature of the Business and Basis of Presentation HTML 56K
(Details)
47: R35 Summary of Significant Accounting Policies - HTML 46K
Schedule of Restricted Cash (Details)
48: R36 Summary of Significant Accounting Policies - HTML 39K
Schedule of Cash, Cash Equivalents and Restricted
Cash (Details)
49: R37 Summary of Significant Accounting Policies - HTML 40K
Schedule of Property, Plant and Equipment
(Details)
50: R38 Summary of Significant Policies - Additional HTML 38K
Information (Details)
51: R39 License, Collaboration, and Funding Agreements - HTML 54K
Genzyme Agreement (Details)
52: R40 License, Collaboration, and Funding Agreements - HTML 39K
Georgetown Agreement (Details)
53: R41 License, Collaboration, and Funding Agreements - HTML 47K
Beth Israel Deaconess Medical Center Agreements
(Details)
54: R42 License, Collaboration, and Funding Agreements - HTML 41K
Research and Development Incentive Program
(Details)
55: R43 License, Collaboration, and Funding Agreements HTML 30K
(Details)
56: R44 Fair Value of Financial Assets and Liabilities - HTML 74K
Measured on a Recurring Basis (Details)
57: R45 Fair Value of Financial Assets and Liabilities - HTML 45K
Debt Securities Available-for-Sale (Details)
58: R46 Fair Value of Financial Assets and Liabilities - HTML 53K
Narrative (Details)
59: R47 Fair Value of Financial Assets and Liabilities HTML 55K
-Aggregate Fair Value of Warrant and Derivative
Liabilities (Details)
60: R48 Fair Value of Financial Assets and Liabilities - HTML 50K
Assumptions (Details)
61: R49 Fair Value of Financial Assets and Liabilities - HTML 42K
Goodwill Rollforward (Details)
62: R50 Property and Equipment, Net (Details) HTML 49K
63: R51 Accrued Expenses (Details) HTML 39K
64: R52 Long-Term Debt - Schedule of Long-Term Debt HTML 41K
(Details)
65: R53 Long-Term Debt - Narrative (Details) HTML 63K
66: R54 Long-Term Debt - Hercules Loan Agreements HTML 35K
(Details)
67: R55 Long-Term Debt - Future Principal Payments HTML 37K
(Details)
68: R56 Leases (Details) HTML 79K
69: R57 Leases - Schedule of Components of Lease Expense HTML 47K
(Details)
70: R58 Leases - Schedule of Maturities of Lease HTML 44K
Liabilities (Detail)
71: R59 Preferred and Common Stock Warrants - Additional HTML 84K
Information (Details)
72: R60 Preferred and Common Stock Warrants - Schedule of HTML 50K
Outstanding Warrants (Detail)
73: R61 Preferred and Common Stock Warrants - Summary of HTML 103K
Outstanding Warrants to Purchase Shares of Common
Stock (Details)
74: R62 Common Stock, Redeemable Common Stock and HTML 192K
Convertible Preferred Stock (converted to Common
Stock) - Additional Information (Details)
75: R63 Stock-Based Compensation - Additional Information HTML 94K
(Details)
76: R64 Stock-Based Compensation - Summary of Stock Option HTML 79K
Activity (Detail)
77: R65 Stock-Based Compensation - Restricted Stock Units HTML 38K
(Details)
78: R66 Stock-Based Compensation - Summary of Stock-Based HTML 42K
Compensation Expense Classification (Details)
79: R67 Stock-Based Compensation - Stock Option Valuation HTML 52K
(Details)
80: R68 Income Taxes - Schedule of Income Loss Before HTML 37K
Income Taxes (Details)
81: R69 Income Taxes - Reconciliation of Effective Income HTML 44K
Tax Rate (Details)
82: R70 Income Taxes - Deferred Income Tax Asset (Details) HTML 50K
83: R71 Income Taxes - Narrative (Details) HTML 48K
84: R72 Income Taxes - Deferred Tax Valuation Allowance HTML 33K
(Details)
85: R73 Income Taxes (Details) HTML 31K
86: R74 Net Loss per Share - Summary of Basic and Diluted HTML 65K
Net loss per Share Attributable to Common
Stockholders (Details)
87: R75 Net Loss per Share - Additional Information HTML 39K
(Details)
88: R76 Net Loss per Share - Schedule of Anti-dilutive HTML 38K
Securities Excluded from Computation of Diluted
Net Loss per Share Attributable to Common
Stockholders (Details)
90: XML IDEA XML File -- Filing Summary XML 170K
93: XML XBRL Instance -- xfor-20231231_htm XML 1.90M
89: EXCEL IDEA Workbook of Financial Report Info XLSX 199K
9: EX-101.CAL XBRL Calculations -- xfor-20231231_cal XML 190K
10: EX-101.DEF XBRL Definitions -- xfor-20231231_def XML 760K
11: EX-101.LAB XBRL Labels -- xfor-20231231_lab XML 1.70M
12: EX-101.PRE XBRL Presentations -- xfor-20231231_pre XML 1.22M
8: EX-101.SCH XBRL Schema -- xfor-20231231 XSD 212K
91: JSON XBRL Instance as JSON Data -- MetaLinks 523± 804K
92: ZIP XBRL Zipped Folder -- 0001628280-24-012578-xbrl Zip 586K
1.I have reviewed this Annual Report on Form 10-K of X4 Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
